Tips For Startups: How To Make Sure Your IP Is Working For You

Two things that startups never seem to have enough of are: time and money. It can be difficult to carve out enough of both to properly identify, manage, and protect your intellectual property (IP). Your IP, including your patents, industrial designs and trademarks, is at the center of your company’s value. As a result, protecting your IP is crucial and will give your company the boost it needs to succeed in a competitive marketplace. Knowing your IP is essential to identifying your competitive advantage, focusing your R&D efforts, and creating an innovative company culture. IP should be the main component of your business plan and your pitch to customers and investors as it is normally your main selling point.

As a startup, you already have passion for your business, and you are convinced that you will be successful. Now, in order to apply your passion to the right strategy, you should ask yourself a series of questions to help pinpoint and identify what IP you currently possess and if it is valuable:

  • What you are doing that is new? What new features have you added, or improvements have you made lately?
  • What makes your product better, or faster, or more accurate, or more efficient than your competitor’s products?
  • What features of your product do customers value the most when making purchasing decisions?
  • Is your company name or logo unique in your industry? Did you check to make sure no one else has it registered as a trademark?
  • Have you designed a new product with a distinctive name, product shape, physical design or packaging?
  • Once you choose your name and logo, have you been consistently using it on your products, packaging, marketing materials, your website and your social media? Document the date you first used it!

One way to answer these questions is to formally evaluate your IP, you could use an IP law firm to do it, which is always recommended but you could also try to figure it out yourself by doing some market and competitor research.

Ideas born from your IP evaluation can form the basis for the future direction of your R&D, which will eventually turn into more patents, industrial designs, and trademarks that you will want to protect and leverage going forward.

Now that you have defined your “secret sauce” you can use it in several ways:

  • File a patent to demonstrate that you have a technological advantage important enough that you are willing to invest in a patent to protect it.
  • Gain credibility with financial investors and VCs. Include it in your pitch and highlight it in your business plan.
  • Get your sales and marketing people to highlight the IP incorporated into your products when interacting with customers.
  • Use your IP to develop and foster a culture of innovation in your company. Celebrate inventors to encourage the generation of new ideas.
  • Leverage your IP to form strategic partnerships and alliances to scale up your business or license out your IP for royalty revenue.
  • Build and protect your brand by consistently monitoring your trademarks to make sure no competitors are using them, and cause customers to mistake a competitor’s product for yours.

Your IP is already there. However, you need to take the time to identify it, protect it, then learn how to artfully articulate it to investors and customers to get the most out of it.

For more information, please contact:

T: 613-567-0762
E: general@mbm.com

Author: David Fraser, Patent Agent

 

This article is general information only and is not to be taken as legal or professional advice. This article does not create a solicitor-client relationship between you and MBM Intellectual Property Law LLP. If you would like more information about intellectual property, please feel free to reach out to MBM for a free consultation.

Importance of Determining Inventorship Prior to Patent Issuance

Determining inventorship, prior to patent issuance, can save an applicant the costly procedural and evidentiary burden required for correcting the named inventors post patent issuance. Since Canadian patent law requires that each patent application list the sole inventor(s) of the claimed invention, divisional applications derived from an application having two or more inventors must list only the inventors that contributed to the claimed invention.

Although a patent may still be issued for an application not listing the sole inventor(s) of the claimed invention, the patentee may be required to correct the records of the Patent Office to reflect the sole inventor(s). However, post patent issuance, to correct the records of the Patent Office, the patentee must bring an application to the Federal Court (“Court”). In doing so, the patentee must follow the evidentiary and procedural requirements for removing a named inventor and/or adding an inventor to the named inventors of the issued patent. This was the case in Inguran LLC dba STgenetics v Commissioner of Patents, 2020 FC 338, for which the patentee, STgenetics, brought an application to the Court for an order to remove six of the twelve named inventors from the records of the Patent Office relating to four issued patents.

To obtain the order for removing named inventors, STgenetics had to meet the test outlined in Imperial Oil Resources Ltd v Canada (Attorney General), 2015 FC 1218. The test asks two questions:

 1. Does it appear that one or more of the named inventors have no part in the invention? and

2. Has an affidavit been provided to satisfy the Court that the remaining inventors are the sole inventors?

In order to meet the test, STgenetics provided affidavits from both inventors determined to have contributed to the issued patents and from non-inventors incorrectly named as inventors. The determined inventors deposed that they contributed to the issued patents, and the non-inventors deposed that they did not contribute to the issued patents.

Based on STgenetics’ evidence, the Court determined that STgenetics met the procedural and evidentiary burden required for removing the names of the non-inventors. Accordingly, the Court ordered the Commissioner of Patents (“Commissioner”) to vary the records of the Patent Office with respect to the inventorship of the issued patents.

Although STgenetics’ application to the Court was successful, the application and the evidentiary burden to satisfy the Court of the relevant jurisprudential tests and procedural requirements could have been avoided had the inventorship been determined prior to the issuance of the patents. STgenetics, could have simply, prior to receiving the notice of allowance, requested the Commissioner to remove the names of the non-inventors and submitting the affidavits. Had STgenetics done so, it could have saved the time and money spent in pursuing the Court application.

 

For more information please contact:

Jamal Hakimi, Patent Lawyer
T: 613-801-0509
E: jhakimi@mbm.com

This article is general information only and is not to be taken as legal or professional advice. This article does not create a solicitor-client relationship between you and MBM Intellectual Property Law LLP. If you would like more information about intellectual property, please feel free to reach out to MBM for a free consultation.

Common Patent Misconceptions – Myth #2

This article is part of a series on commonly held misconceptions about patents. Many prospective patentees often have unfounded reservations about patenting their inventions. The aim of this series of short articles is to debunk these common myths around patent protection.

Patent Myth #2I don’t need a patent because I’m the only one with this technology, no one else will be able to enter the market.

This surprisingly common belief is in some ways related to Patent Myth #1. Having a quick read of that article may help with understanding the connection to this piece.

Many startups and even some SMEs often hold the view that because they were the first to come up with a particular technology that fact will somehow serve as a natural barrier to entry for others. While this may be true in some rare cases, these companies often fail to realize that other, often larger entities have well-established R&D departments that, among other reasons, are there to understand competing technologies and, in some cases, learn to reverse engineer them.

In Patent Myth #1, we touched on the case of Microsoft Corp. v. i4i Ltd. Partnership, 564 U.S. 91 (2011), where the Supreme Court of the United States (“SCOTUS”) found Microsoft to have infringed the patent of a much smaller Toronto-based company. In that case, the Canadian company, i4i was successful first and foremost because it had a patent for its document editing invention. If i4i had instead chosen not to file a patent, there would have been no infringement even if Microsoft used or copied their technology. At the very least i4i would have been gambling with the time and money they invested in developing their software.

This discussion also ties into the law of trade secrets in that a company certainly could choose to maintain its invention as a trade secret, but it may not always be appropriate. The Canadian Intellectual Property Office (“CIPO”) website states: “Trade secrets can be very valuable when you have developed new technology, designed original products, created the perfect recipe, or have a gold mine of customer data. However, it may not be the best choice of intellectual property (IP) protection if your competitors can easily reconstruct your creation.” The last sentence is precisely what companies should be thinking about when considering a patent. Even if you are the first to bring something to market, it is important to keep in mind that someone might still be able to dissect and understand it.

Never forget that maintaining a trade secret as a secret has its own challenges, and even something like a disgruntled former employee can put a trade secret into a risk of being publicized. As CIPO states, “Once a trade secret is made public, it loses its business value and legal remedies are complex.” Even if someone breaches an agreement and has to ultimately pay damages, that trade secret can still never go back to being a secret, so its value is irretrievably lost.

One final note relates to the “on sale bar” in the United States. In January 2019, SCOTUS decided in a landmark decision, Helsinn Healthcare v. Teva Pharma USA, 586 U. S. ____ (2019), that “an inventor’s sale of an invention to a third party who is obligated to keep the invention confidential can qualify as prior art under §102(a).” This means that even if an invention is sold as a trade secret, it could prevent the inventor from later obtaining a patent for it. Many inventors believe they’ll be able to profit from their invention as a trade secret for some years before they file for patent protection, but this approach may be risky, if not dangerous.

Could someone reverse engineer and/or copy your invention? If you think the answer is yes, then it’s likely you should look into obtaining patent protection. Please feel free to reach out to MBM for a free consultation.

T: 613-567-0762
E: patents@mbm.com

Author: Osman Ismaili, Patent Associate

 

This article is general information only and is not to be taken as legal or professional advice. This article does not create a solicitor-client relationship between you and MBM Intellectual Property Law LLP. If you would like more information about intellectual property, please feel free to reach out to MBM for a free consultation.

Absence of a Canadian patent leaves the PMPRB powerless to control the price of Cystadrops

While the Patented Medicines Prices Review Board (“the PMPRB”) polices the prices of patented medicines in Canada, a recent article in The Globe and Mail suggested that a loophole may exist for drug manufacturers that have chosen not to acquire Canadian patent protection.

Cystadrops, a cysteamine hydrochloride-based eye drops formulation is produced by Recordati Rare Diseases Inc. (“Recordati”), and is used to treat a rare disease known as cystinosis. Cystinosis is characterized by the abnormal accumulation of the amino acid cystine in various organs of the body, including crystal build up in the eyes. While about one hundred Canadians suffer from cystinosis, the cost for a year’s supply of Cystadrops is approximately $111,000 per individual.

This price is largely due to the fact that Cystadrops does not fall within the jurisdiction of the Canadian federal regulatory body for medicines pricing. As Recordati chose not to obtain a Canadian patent for its formulation, any price regulation for Cystadrops by the PMPRB would be ultra vires. Compounding pharmacies in Canada largely stopped making cheaper versions of the drug when Recordati’s version was given the green light by Health Canada.

Another interesting aspect to note is that typically data privacy regimes provide innovative drugs with a data protection period of eight or eight and a half years, during the first 6 of which a (typically generic) manufacturer seeking a Notice of Compliance (“NOC”) will be prevented from filing its drug submission.

A search of the Register of Innovative Drugs has revealed that while there is no active data protection over Cystadrops, a related formulation of cysteamine bitartrate is protected and is associated with another company. Whether any patent or NOC links exist between the two formulations, or another third party for that matter, remains unclear. Furthermore, perhaps the very small market of just one hundred people acts a natural barrier to entry for generics or compounding pharmacies to invest in preparing the formulation.

With drug pricing regulations already being a contentious issue in Canada, it will certainly be of interest to see how this particular situation will develop, or if more information will be brought to light. In any case, as a result of the price of Cystadrops, Ontario became the first province to fund the drug, with other provinces expected to follow suit.

T: 613-567-0762
E: patents@mbm.com

Authors: Osman Ismaili, Patent Associate

 

This article is general information only and is not to be taken as legal or professional advice. This article does not create a solicitor-client relationship between you and MBM Intellectual Property Law LLP. If you would like more information about intellectual property, please feel free to reach out to MBM for a free consultation.

Common Patent Misconceptions – Myth #1

This article is part of a series on commonly held misconceptions about patents. Many prospective patentees often have unfounded reservations about patenting their inventions. The aim of this series of short articles is to debunk these common myths around patent protection.

Patent Myth #1: Even if I file and register a patent, some giant company could still infringe it and would probably win in court if I sued them.

First and foremost, the likelihood of a patent ending up in court is very low. Economic studies (http://faculty.haas.berkeley.edu/shapiro/patents.pdf) have shown that of the total number of patents that are issued every year, only about 1.5% of them are ever litigated, and that only about 0.1% of them are ever litigated to trial. The association between patents and litigation in the minds of the public is likely a result of the relatively more recent patent troll cases, and the disproportionately high media coverage they have received.

If the statistics aren’t enough, businesses and startups should also keep in mind that the laws and regulations in place will not likely allow a smaller company to be unfairly steamrolled in court by a much larger infringer. A good example of this is the case of Microsoft Corp. v. i4i Ltd. Partnership, 564 U.S. 91 (2011), where the Supreme Court of the United States (“SCOTUS”) unanimously upheld a $290 million award against the tech giant Microsoft in a case brought by a Canadian software startup, i4i Limited Partnership (“i4i”). The Toronto-based i4i had alleged that a version of Microsoft Word had infringed its patented method for editing documents.

While litigation can certainly be expensive, and while Microsoft did have much deeper pockets than i4i, the SCOTUS decision, and indeed the lower courts, agreed that Microsoft had willfully violated i4i’s patent rights and that i4i was due compensation for that infringement.

A key take away from the above example is that the success of i4i would never have been possible had they not acquired patent protection for their invention. Without their patent, Microsoft would have been freely able to use the technology, with any recourse for i4i being highly unlikely.

If you are considering obtaining patent protection or have questions relating to patent protection, please feel free to reach out to MBM for a free consultation

T: 613-567-0762
E: patents@mbm.com

Author: Osman Ismaili, Patent Associate

 

This article is general information only and is not to be taken as legal or professional advice. This article does not create a solicitor-client relationship between you and MBM Intellectual Property Law LLP. If you would like more information about intellectual property, please feel free to reach out to MBM for a free consultation.

 

Are you utilizing your IP to obtain financing and grow your business?

Intellectual property (IP), including patents, industrial designs and trademarks, is an under-utilized business tool for small medium enterprises (SMEs).  Regardless of company size, IP may be used to:

  • Obtain financing
  • Generate revenue through licensing opportunities
  • Protect and/or expand market share

This is highlighted in the 2019 IP Canada Report from the Canadian Intellectual Property Office in the section entitled “[t]he impact of IP on financing and growth of small and medium enterprises” (https://www.ic.gc.ca/eic/site/cipointernet-internetopic.nsf/eng/h_wr04682.html). In particular, the 2019 IP Canada Report summarized the results of ISED 2017 Survey on Financing and Growth of Small Medium Enterprises.  The following points are of particular interest:

  • While more than half of Canadian SMEs are aware of patents, very few have patents.
  • The proportion of Canadian SMEs holding at least one patent increases as size of SMEs increases.  In particular, 3% of SMEs having 20 to 99 employees hold at least one patent while 15% of SMEs having 100 to 499 employees hold at least one patent.
  • Canadian SMEs aware of IP or holding formal IP obtained more financing as compared to SMEs not aware or not using IP.
  • Canadian SMEs aware of IP or holding formal IP increased domestic and international market expansion as compared to SMEs not aware or not using IP.
  • Canadian SMEs aware of IP or holding formal IP increased growth as compared to SMEs not aware or not using IP.

It is important to start a formal conversation about some forms of IP at the outset of your business, even if you don’t have the funds to invest in it right away. A strategy should be devised to plan for it in the future and allocate some budget to properly protect your IP. An intellectual property professional can help you determine what IP is appropriate for your business and how much to budget for it. Intellectual property, especially for start-ups or an SMEs, is considered to be one of its biggest business assets and as such should be treated with extreme care. An IP professional can help you maximize business opportunities out of your intellectual property if the right strategy is in place.

For more information please contact:

Kay Palmer, Ph.D., Senior Patent Agent
T: 613-801-0452
E: kpalmer@mbm.com

This article is general information only and is not to be taken as legal or professional advice. This article does not create a solicitor-client relationship between you and MBM Intellectual Property Law LLP. If you would like more information about intellectual property, please feel free to reach out to MBM for a free consultation.

 

Review of the Last 100 Decisions of the Canadian Commissioner of Patents

The Canadian Commissioner of Patents with the assistance of the Patent Appeal Board (PAB) review patent applications that were rejected by Examiners during prosecution. The PAB is an advisory body that includes a Chair and several senior officials of the Patent Office with previous experience as patent examiners. The members of the PAB have not participated in the prosecution of the application to ensure that the review is impartial.

We have conducted an informal review of the last 100 Commissioner’s decisions to gain insight into what type of rejections are being appealed to the Commissioner of Patents and what an Applicant’s likelihood of success is. The decisions were issued between March 23, 2016 and August 5, 2019.

Out of 100 decisions:

12 of the applications under review ultimately issued to patent.

  • 7 of the 12 cases that ultimately issued to patent, the rejections were not considered justified.
  • 5 of the 12 cases that ultimately issued to patent required PAB directed amendments.
  • Only 1 of the 12 cases that ultimately issued to patent included a subject matter rejection.
  • 7 of the 12 cases that ultimately issued to patent included an obviousness rejection.
  • 7 of the 12 cases related to biological or chemical fields.

88 of the applications under review ultimately did not issue to patent.

  • In almost half of these cases a statutory subject matter rejection was made.
  • In 23 of these cases, the only rejection was the statutory subject matter rejection.
  • 17 of these 23 cases included rejections relating to the meaning of art.
  • 21 of these 23 cases included rejections that the claims were directed to a mere plan.
  • 56 of these cases included an obviousness rejection.

Based on our informal review of the last 100 decisions, we believe that Examiner’s decisions to reject applications are generally in-line with the PAB. We further believe the Patent Office will require clarification from the Federal Court with respect to subject matter rejections.

For more information please contact:

Claire Palmer, Ph.D., Senior Patent Agent
T: 613-801-0450
E: cpalmer@mbm.com

 

This article is general information only and is not to be taken as legal or professional advice. This article does not create a solicitor-client relationship between you and MBM Intellectual Property Law LLP. If you would like more information about intellectual property, please feel free to reach out to MBM for a free consultation.

 

Amendments to the Canadian Patent Rules: Key Changes & Their Impact on the Patent Practice in Canada

Canada has revised its patent regime to implement the Patent Law Treaty. The new Patent Rules along with corresponding amendments to the Patent Act are set to come into force on October 30, 2019. Most of the changes are intended to streamline and harmonize administrative procedures and formalities with other international intellectual property offices.

Below is a summary of the most noteworthy changes that would require significant practice adjustments and preparation by both the applicants and the agents.

WITH RESPECT TO PCT APPLICATIONS FILED ON OR AFTER OCTOBER 30, 2019:

1. Elimination of “Late” national phase entry at 42-months as a matter of right

The current practice allows an applicant to enter CA national phase after the 30-month deadline and up to 42 months from the priority date, as a matter of right, by paying a $200 late entry fee.

Under the new Rules, the “late” entry is only possible by submitting a statement to the Canadian Intellectual Property Office (CIPO) that the failure to enter the national phase at the 30-month deadline was “unintentional”, in addition to the required filing fee and a $200 late entry fee for reinstatement of rights. Canadian Intellectual Property Office (CIPO) still reserves the right to accept or reject this statement.

It is therefore advisable going forward to consider the 30-month national phase entry deadline as a non-extendible deadline under the new Rules.

2. Translation required at the time of national phase entry

Submission of the English or French translation for a foreign language patent application is an absolute requirement in order to submit an application in Canada.

3. Filing fee required at the time of national phase entry

Payment of filing fee is an absolute requirement to enter the national phase in Canada, with an exception that if an attempt to make a fee payment at the time of filing is unsuccessful, then the filing fee can be paid within 2 months from the date of the attempted payment.

4. Certified copies of priority documents required at the time of filing

If the certified copies of the priority application were not filed during the international phase, it will be necessary at the time of national phase entry in Canada to submit a copy to CIPO, or refer to a digital library that is accepted by CIPO.

5. Restoration of priority

CIPO will accept the restoration of priority attained at the International Phase. If priority is not restored at the international phase, then the priority may be restored in the Canadian national phase application by filing a request within one month from date of the national phase entry, along with establishing that restoration is required due to an unintentional error.

WITH RESPECT TO DIRECT ENTRY APPLICATIONS BASED ON PARIS CONVENTION FILED ON OR AFTER OCTOBER 30, 2019:

1. Filing fee and translation NOT required at the time of filing

The payment of the filing fee can be delayed up to 3 months from the date of the Notice issued by CIPO, along with a $150 late fee.

The submission of the English or French translation for a foreign language patent application can be delayed up to 2 months from the date of the Notice issued by CIPO.

2. Certified copies of priority documents are required within 4 months from the filing or 16 months from the earliest priority date

If certified copies of each priority document are not submitted or made available to CIPO from a digital library within the prescribed time, then CIPO will issue a Notice.

Failure to comply with the requirements by the date set by the Notice would result in the priority claim being considered to have been withdrawn.

3. Restoration of priority

Restoration of priority is available if the Canadian application is filed within 14 months of the priority date, and a request for restoration is filed within 2 months from the Canadian filing date, along with the statement that the error was unintentional.

ABANDONMENT AND REINSTATEMENT OPTIONS

Under current practice, if a Canadian patent application (National Phase or Direct Entry) is deemed abandoned for failure to comply with a due date established for any of the actions described below, the application can be reinstated within 12 months from the date of abandonment by requesting reinstatement, paying a $200 government fee, and taking the action that was required to avoid abandonment.

Under the new Rules, the date of abandonment and reinstatement procedures vary depending upon the cause for abandonment.

For failure to request examination due on or after October 30, 2019

  • CIPO will issue a Notice requiring that the request for examination be filed with payment of the exam fee and a $150 late fee within 2 months of the date of the Notice.
  • The application can be maintained in good standing by requesting examination and paying the $150 late fee prior to the due date set by the Notice.
  • Failure to comply with the requirements set out in the Notice will result in abandonment of the application. Reinstatement can be requested within the 12 month period after the date of abandonment.
  • Within 6 months from the original examination deadline, the application can be reinstated, as a matter of right, by requesting examination, paying the $150 late fee and a $200 reinstatement fee.
  • After 6 months from the original examination deadline, the application can only be reinstated if the applicant can also establish to the commissioner’s discretion that the deadline was missed despite the “due care” required by the circumstances was taken.

For failure to pay maintenance fee due on or after October 30, 2019 for a pending application or a patent

  • CIPO will issue a Notice requiring that the maintenance fee be paid with a $150 late fee by the later of: either 2 months after the date of the Notice or 6 months after the missed deadline.
  • The application can be maintained in good standing by paying the maintenance fee and the $150 late fee prior to the due date set by the Notice.
  • Failure to comply with the requirements set out in the Notice will result in abandonment of the application. Reinstatement can be requested with the 12 month period after the date of abandonment.
  • After the abandoned date, the application can only be reinstated if the applicant can establish to the commissioner’s discretion that the deadline was missed despite the “due care” required by the circumstances was taken, and by paying the maintenance fee, the $150 late fee and a $200 reinstatement fee.

For failure to respond to an Office Action mailed on or after October 30, 2019

  • If a response is not submitted by the due date of 4 months from the date of the requisition (extendible up to 2 months), the application will be deemed abandoned immediately.
  • The reinstatement procedure remains unchanged from current practice, and the application can be reinstated within 12 months of the date of the abandonment, as a matter of right, by submitting the outstanding Office Action response, requesting reinstatement and paying a $200 government fee.

For failure to pay final fee in response to a Notice of Allowance mailed on or after October 30, 2019

  • If the final fee is not paid by the due date of 4 months from the date of the Notice of Allowance, the application will be deemed abandoned immediately.
  • Reinstatement procedure remains unchanged from current practice, and the application can be reinstated within 12 months of the date of the abandonment, as a matter of right, by paying the final fee, requesting reinstatement and paying a $200 government fee.

THIRD PARTY RIGHTS

The new rules introduce the notion of third-party rights to use the invention post-grant, if an applicant fails to pay their maintenance fees and/or to request examination within 6-months from the initial due date (and the due date is after October 30, 2019).

These third-party rights limit the liabilities faced by a third party when a patent application is reinstated or a patent is restored 6 months after the initial due date by paying the maintenance fees and/or if the application is reinstated 6 months after the initial due date for requesting examination.

Given the broad language of these new rules, patent owners will need to consider carefully before delaying the payment of maintenance fee outside the initial 6 months window as they may lose the ability to enforce against third parties that commit, or make serious and effective preparation to commit, an “infringing” act, not only during the window of reinstatement/restoration period but also potentially for the life of the patent.

To emphasize and highlight: In our opinion the two changes that depart most significantly from the current practice are:

1.  the elimination of the option for “Late National Phase Entry” at 42 months from the priority date as a matter of right.

2.  the introduction of third-party rights to use a patented invention because of non-compliance with deadlines relating to payment of maintenance fees and/or request for examination.

 

For more information, please contact:

Poonam Tauh, Partner & Patent Agent
T: 403-800-9018
E: ptauh@mbm.com

Suzanne Hof, Senior Patent Agent
T: 613-801-0510
E: shof@mbm.com

 

This article is general information only and is not to be taken as legal or professional advice. This article does not create a solicitor-client relationship between you and MBM Intellectual Property Law LLP. If you would like more information about intellectual property, please feel free to reach out to MBM for a free consultation.

Planning ahead: how to protect your business when you’ve licensed-in critical IP and the licensor is going under?

Starting November 1, 2019, important changes are coming into force to the Canadian Bankruptcy and Insolvency Act (BIA) and the Canadian Companies’ Creditors Arrangement Act (CCAA) that are directly related to intellectual property. These changes will better protect licensees of intellectual property when the licensor becomes insolvent by allowing a licensee in good standing to continue to use the licensed IP, despite licensor’s financial troubles.

In particular, the changes clarify that a licensee that “continues to perform its obligations under the agreement in relation to the use of the intellectual property” can continue to use the IP, including enforcement of the use exclusivity, during the term of the agreement, even if:

  • the IP is sold in a BIA restructuring
  • the IP is disclaimed or sold in a BIA liquidation
  • the IP is disclaimed or sold in a receivership
  • the IP is sold in a CCAA restructuring

As a licensee wishing to continue to take advantage of the licensed IP, it is critical that you continue to meet all obligations in the licensing agreement.

In order to properly plan ahead, it is our recommendation that a licensing agreement always include contingency arrangements in the event of the licensor’s insolvency. Always have the licensing agreement reviewed by an IP lawyer. These contingency arrangements should specify:

  • provisions detailing what licensee’s obligations are in the event that a licensor cannot meet their on-going obligations in the event of insolvency.  For example, if a licensor receives payments for on-going support activities, the licensee should specify in the agreement that these payments will be payable only if licensor is able to complete these on-going support activities.
  • provisions detailing who will maintain the IP in good standing in the event that the licensor can no longer continue to financially support the IP.

Having appropriate contingency in place in the event of licensor insolvency will help better protect licensee’s business.

For more information please contact:
Claire Palmer, Senior Patent Agent
T: 613-801-0450
E: cpalmer@mbm.com

 

This article is general information only and is not to be taken as legal or professional advice. This article does not create a solicitor-client relationship between you and MBM Intellectual Property Law LLP. If you would like more information about intellectual property, please feel free to reach out to MBM for a free consultation.

 

Intellectual Property Considerations in the New CPTPP & NAFTA Negotiations

When the United States pulled out of trade negotiations for the Trans-Pacific Partnership agreement (the “TPP”), many considered the agreement to be dead. However, Canada and the other ten countries originally part of TPP negotiations have managed to breathe new life into the agreement.

At the World Economic forum in January 2018 in Davos, Canadian Prime Minister Trudeau announced that Canada and the other ten TPP countries had reached an agreement on a revised TPP,[1] now renamed the Comprehensive and Progressive Agreement for Trans-Pacific Partnership (the “CPTPP”). Member countries are working towards signing the agreement by early March 2018.[2] While the new CPTPP will be different in a number of ways, of particular importance are the changes that were made to the agreement’s intellectual property (IP) provisions following the departure of the US from negotiations.

During the original TPP negotiations, the US had insisted for certain IP provisions related to patentable subject matter, patent term adjustment, copyright term of protection and technological protection measures (TPMs), among others, to be strengthened. At the time, many of these provisions were considered one-sided and quite controversial because they would require other TPP member countries to undergo extensive and expensive legislative reforms, including Canada. In agreeing to the reworked CPTPP, Canada has endorsed the suspension of a number of these IP provisions. A list outlining the suspended IP provisions can be found here.[3]

With this new CPTPP as a backdrop, it will be interesting to see how Canada will now approach the negotiation table with the US for a revised NAFTA. It is expected that the US will attempt to negotiate for IP provisions similar to those in the original TPP.[4] Whether Canada will push back against the US for IP provisions more in line with those in the new CPTPP, only time will tell.

 

For more information, please contact:

Randy Marusyk, Co-Managing Partner
T: 613-801-1088
E: rmarusyk@mbm.com

Co-Author: Robert Di Battista

 

This article is general information only and is not to be taken as legal or professional advice. This article does not create a solicitor-client relationship between you and MBM Intellectual Property Law LLP. If you would like more information about intellectual property, please feel free to reach out to MBM for a free consultation.

 

[1] https://globalnews.ca/news/3989224/commentary-tpp-deal-a-win-for-trudeau-and-a-win-for-canada/

[2] http://www.macleans.ca/politics/ottawa/canada-tpp-members-agree-to-revised-deal-without-the-u-s/

[3] http://dfat.gov.au/trade/agreements/tpp/news/Documents/annex-2.pdf

[4] http://www.michaelgeist.ca/2018/01/dont-make-tpp-mistake-canada-needs-maintain-progressive-approach-ip-nafta

Top Top